Business Context and Reporting Period
This Form 8-K was filed by Manhattan Pharmaceuticals, Inc. (referred to in metadata as TG Therapeutics, Inc.) on January 4, 2011. The report details the entry into a Settlement and Release Agreement with Nordic Biotech Venture Fund II K/S and H Pharmaceuticals K/S (the "Joint Venture") to resolve disputes regarding the development and commercialization of Hedrin, a treatment for head lice.
Key Financial Metrics and Agreements
- Settlement Payment: The Joint Venture agreed to pay the Company $500,000 in two installments ($100,000 immediate; $400,000 contingent on note conversion or extension), subject to deductions for legal costs exceeding $70,000.
- Capital Contribution: Nordic is required to make a non-dilutive capital contribution of $1,500,000 to the Joint Venture (including $300,000 already contributed).
- Services Agreement Payment: The Joint Venture will pay $75,000 to the Company under a terminated Services Agreement.
- Debt Status: The filing notes that $1,315,000 of the Company's 12% Secured Notes has matured and is past due.
- Equity Interest: The Company's equity interest in the Joint Venture is reduced to 15%, with a floor of 5%.
Material Changes Versus Prior Period
- Termination of Rights: The "Put Right" (disputed share ownership between 71.4M and 183.3M shares) and the "Warrant" (disputed share coverage between 14.3M and 33.3M shares) have been terminated.
- Management Changes: Messrs. Michael G. McGuinness and Douglas Abel resigned from the Board of Directors of the Joint Venture.
- Control Shift: The Company no longer has the right to participate in the management of the Joint Venture or its Hedrin assets, retaining only limited rights as a minority partner.
- Contract Termination: The Joint Venture Agreement, Shareholders' Agreement, and Registration Rights Agreement have been terminated and consolidated into a new Limited Partnership Agreement.
Outlook, Risks, and Contingencies
- Contingent Payment: The second installment of the settlement ($400,000) is contingent upon the holders of the past-due 12% Secured Notes either converting to equity or extending the maturity to December 31, 2011.
- Legal Costs: The settlement amount is subject to reduction by "Excess Payment," defined as legal and other costs incurred by Nordic and the Joint Venture exceeding $70,000.
- Liquidity Risk: The existence of $1,315,000 in past-due secured notes indicates potential liquidity constraints.
- Future Dilution: The Company's ownership in the Joint Venture may be further reduced below 15% (but not below 5%) if Nordic makes additional capital contributions.
Investor Verification Checklist
- Verify the status of the $1,315,000 in past-due 12% Secured Notes and whether conversion or extension agreements have been reached.
- Confirm the actual amount of the second settlement installment after calculating any "Excess Payment" deductions for legal costs.
- Review the new consolidated Limited Partnership Agreement to understand the specific "limited rights" retained by the Company as a minority partner.
- Assess the impact of losing management control over the Hedrin asset on the Company's future revenue projections.